A study involving scientists from several universities in the United Kingdom found that when vaccinated against the new coronavirus pneumonia (COVID-19), the time between two doses of "Pfizer vaccine" is prolonged and more antibodies can be produced.
Susanna Dunachie, a professor at the University of Oxford who led the research, pointed out at a briefing on July 21 that after weighing the severity, 8 weeks may be the best interval.
New crown pneumonia epidemic in the United States: The picture shows people in New York, the United States, who made an appointment for the second dose of vaccine after being vaccinated at the American Museum of Natural History on July 22.
"Pfizer Vaccine" is a new coronary pneumonia vaccine jointly developed by the US pharmaceutical company Pfizer (Pfizer) and the German biotech company (BioNTech).
The research team examined the antibodies in 503 medical staff. The interval between their two doses of "Pfizer Vaccine" ranged from 3 to 10 weeks.
New crown pneumonia | A woman who received 2 vaccines before her death is suspected to be the first case of new crown pneumonia in Thailand's mixed vaccine death | Wang Yi opposes vaccine nationalism Portuguese foreign minister: does not support traceability politicization British study: two doses of Pfizer or AstraZeneca vaccine effectively cope with the Delta variant Virus
The study found that regardless of the length of the interval, after the second dose of the vaccine, there will be a strong immune response, but the level of neutralizing antibodies from the second dose of vaccine after 10 weeks is twice that of the three weeks.
The trial has covered mutated strains of the new coronavirus, including Delta.